Physician profile
Devin Patel
NPI 1629463443
$1,168.74
in general payments reported to CMS, 2019-2025
19 companies · $229 in 2025
The $229 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $264 · 2020: $115 · 2022: $186 · 2023: $230 · 2024: $145 · 2025: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $604.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $603.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $169.65 | 2022-2024 | Briviact |
| Pfizer INC. | $156.09 | 2019-2025 | |
| Gilead Sciences, INC. | $124.91 | 2022-2025 | Veklury |
| Cardinal Health 200 LLC | $91.80 | 2019 | |
| Lilly USA, LLC | $78.56 | 2020 | |
| Melinta Therapeutics, LLC | $78.38 | 2022-2025 | Orbactiv, Kimyrsa, Rezzayo |
| Abbvie INC. | $72.15 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $68.91 | 2019 | |
| Janssen Pharmaceuticals, INC | $66.27 | 2022-2024 | Xarelto |
| La Jolla Pharmaceutical Company | $59.37 | 2023-2024 | Xerava |
| Insmed, INC. | $44.50 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.63 | 2019-2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $22.29 | 2025 | |
| Mylan Specialty L.P. | $21.83 | 2020 | |
| Resmed Corp | $18.09 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $15.86 | 2023 | Dificid, Zerbaxa, Recarbrio |
| E.R. Squibb & Sons, L.L.C. | $14.90 | 2020 | |
| Ferring Pharmaceuticals INC. | $14.86 | 2022 | |
| Chiesi USA, INC. | $14.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devin Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.